The American Cancer Society (ACS) and Pfizer Inc. (NYSE: PFE) have jointly unveiled the “Change the Odds: Uniting to Improve Cancer Outcomes™” initiative, a three-year program aimed at addressing disparities in cancer care. With $15 million in funding from Pfizer,…
Novo Nordisk has announced its agreement to acquire three fill-finish sites from Novo Holdings A/S as part of the transaction where Novo Holdings will acquire Catalent, Inc., a global contract development and manufacturing organization headquartered in Somerset, New Jersey (US).…
Eli Lilly and Company (NYSE: LLY) disclosed its financial outcomes for the final quarter of 2023, marking a year of notable accomplishments characterized by substantial revenue growth. David A. Ricks, Lilly’s chair and CEO, emphasized the company’s impactful contributions in…
FDA Grants Fast Track Designation to BioNTech and DualityBio for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305 BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for BNT325/DB-1305…
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; referred to as “Shionogi”) has revealed that Pixie Dust Technologies, Inc. (Head Office: Tokyo, Japan; Representative Directors: Yoichi Ochiai and Taiichiro Murakami; referred to as “PxDT”)…
Bio-Techne Corporation (NASDAQ: TECH) has released its financial results for the second quarter ending December 31, 2023. Key Highlights for the Second Quarter of Fiscal Year 2024: Bio-Techne’s financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP).…
Teva Announces Plan to Sell its Active-Pharmaceutical Ingredient (API) Business, ‘TAPI,’ as a Strategic Move Towards Growth Teva disclosed today its decision to divest its active-pharmaceutical ingredient (API) business, known as “TAPI.” A prominent player in the global small-molecule API…
Grifols, a distinguished global healthcare company with a 115-year legacy as a leading manufacturer of plasma-derived medicines, has bolstered its senior management team through two strategic appointments. Dr. Roland Wandeler assumes the role of President for the Biopharma Business Unit,…
E. Merck KG Announces Results of Board Election E. Merck KG, the entity holding approximately 70 percent of Merck KGaA on behalf of the Merck family, revealed the outcomes of its routine board elections held over the weekend. Johannes Baillou…
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced the establishment of Regeneron Cell Medicines, marking a strategic agreement with 2seventy bio, Inc. to acquire complete development and commercialization rights to its portfolio of novel immune cell therapies. This acquisition encompasses preclinical…
Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has approved a manufacturing process change resulting in a shorter manufacturing time for Yescarta® (axicabtagene ciloleucel). With this approval, Kite’s median turnaround time (TAT) in…
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have announced an amendment to their collaboration agreement, along with a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share. This equity…